Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

• Conditions: Lymphoblastic Lymphoma

• Registration Number: NCT03571997
• Lead Sponsor: PETHEMA Foundation

Brief Summary

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present

Detailed Description

Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present. Analysis of the main clinical-biological variables as independent risk factors in adult patients (\> 15 years) diagnosed with ALL

Study Timeline

• Study Start: 2018-06-15
• Study First Submitted: 2018-06-18
• Study First Submitted QC: 2018-06-18
• Study First Posted: 2018-06-28
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-31
• Last Update Posted: 2022-02-01
• Primary Completion: 2022-12-30
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients >15 years old diagnosed with ALL and treated with the PETHEMA protocols for ALL

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description pronostic factors	1 year	Study of the main clinical-biological variables as independent risk factors in adult patients (\> 15 years) diagnosed with ALL

Secondary Outcome Measures

Name	Time	Method
Progression free survival	1 year	To study if there has been an increase in progression-free survival (PFS) in patients diagnosed with ALL in the different PETHEMA protocols
overall survival	1 year	To study if there has been an increase in overall survival (OS), in patients diagnosed with ALL in the different PETHEMA protocols

Trial Locations

Locations (28)

Hospital Central de Asturias; 🇪🇸 Oviedo, Asturias, Spain

H. de la Santa Creu I Sant Pau; 🇪🇸 Barcelona, Spain

H. Vall d'Hebron, Barcelona; 🇪🇸 Barcelona, Spain

Hospital Mútua de Terrassa; 🇪🇸 Terrassa, Barcelona, Spain

Hospital General de Alicante; 🇪🇸 Alicante, Spain

H.Universitari Germans Trias I Pujol de Badalona; 🇪🇸 Barcelona, Spain

Hospital Clínic de Barcelona; 🇪🇸 Barcelona, Spain

Hospital de Basurto; 🇪🇸 Basurto, Spain

ICO-Duran i Reynals; 🇪🇸 Bellvitge, Spain

Hospital Donostia; 🇪🇸 Donostia, Spain

H. Univ. de Girona Dr. Josep Trueta (ICO); 🇪🇸 Girona, Spain

Hospital Arnau de Vilanova (Lleida); 🇪🇸 Lleida, Spain

Hospital Lucus Augusti; 🇪🇸 Lugo, Spain

H. Gregorio Marañón; 🇪🇸 Madrid, Spain

Hospital General Universitario Morales Messeguer; 🇪🇸 Murcia, Spain

Parc Taulí; 🇪🇸 Sabadell, Spain

Hospital San Pedro de Alcántara.; 🇪🇸 Málaga, Spain

Hospital Son Espases; 🇪🇸 Palma De Mallorca, Spain

Hospital Son Llatzer; 🇪🇸 Palma de Mallorca, Spain

Complejo Hospitalario de Navarra; 🇪🇸 Pamplona, Spain

C. H. U. de Santiago; 🇪🇸 Santiago de Compostela, Spain

H. Univ. de Salamanca; 🇪🇸 Salamanca, Spain

Complejo Hosp. Regional Virgen del Rocío; 🇪🇸 Sevilla, Spain

Hospital del Valme; 🇪🇸 Sevilla, Spain

Hospital Arnau de Vilanova (Valencia); 🇪🇸 Valencia, Spain

Hoapital La Fe; 🇪🇸 Valencia, Spain

H. Joan XXIII; 🇪🇸 Tarragona, Spain

Hospital Universitari Clínic València; 🇪🇸 Valencia, Spain